Chemotherapy Drug Market is expected to reach USD 89,338.07 million by 2029

Cancer is the second biggest cause of mortality worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018. As cancer rates rise, so will demand for chemotherapy medications. Chemotherapy is a type of cancer treatment in which medications are used to kill a large number of rapidly developing cells in the body. Chemotherapy is effective in reducing the number of cancer cells in the body, slowing cancer progression, and shrinking tumors.

Data Bridge Market Research analyses that the chemotherapy drug market was valued at USD 42,909.37 million in 2021 and is expected to reach USD 89,338.07 million by 2029, registering a CAGR of 9.60% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Read More :
https://www.databridgemarketresearch.com/reports/global-chemotherapy-drug-market

Market Definition

Chemotherapy is the most common type of cancer treatment drug. Chemotherapy is used to slow or stop the growth of cancer cells. Chemotherapy primarily targets malignant cells that are rapidly developing. Chemotherapy is the use of a chemical substance to stop cancer cells from growing. Chemotherapy medications come in a variety of forms. Adriamycin, Taxotere, Ellence, Paraplatin, Taxol, Cytoxan, Navelbine, Ixempra, Xeloda, Abraxane, Gemzar, and Halaven are some of the chemotherapy medications commonly used for adjuvant and neoadjuvant chemo. All of these chemotherapy medicines target various stages of the cell cycle. Drugs can be given as monotherapy or in combination therapy during chemotherapy.

Recent Development

In May 2022, Gland Pharma had announced the launch of Bortezomib for Injection in US market. Bortezomib for injection is employed for treating certain types of cancer including multiple myeloma and mantle cell lymphoma.

Some of the major players operating in the chemotherapy drug market are:

F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Ireland)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Eli Lilly and Company (U.S.)
Merck & Co., Inc. (U.S.)
Allergan (Ireland)
AstraZeneca (U.K.)
AbbVie Inc. (U.S.)
Johnson & Johnson Private Limited (U.S.)
Cipla Inc. (U.S.)
Abbott (U.S.)
Merck KGaA (Germany)
LEO Pharma A/S (Denmark)
Bausch Health Companies Inc. (Canada)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
Hikma Pharmaceuticals PLC (U.K.)
Fresenius Kabi AG (Germany)
Amneal Pharmaceuticals LLC. (U.S.)

More Links:

https://dbmrbuisness.blogspot.com/2023/07/global-viral-hepatitis-market-industry.html

https://dbmrbuisness.blogspot.com/2023/07/global-surgical-simulator-market.html

https://dbmrbuisness.blogspot.com/2023/07/global-neuromyelitis-optica-spectrum.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.